BRAF Mutation is Associated with an Improved Survival in Glioma-a Systematic Review and Meta-analysis

Overview

Journal Mol Neurobiol

Specialties Molecular Biology
Neurology

Date 2017 May 24

PMID 28534272

Citations 29

Authors

Huy Gia Vuong

Ahmed M A Altibi

Uyen N P Duong

Hanh T T Ngo

Thong Quang Pham

Kar-Ming Fung

Lewis Hassell

Affiliations

Soon will be listed here.

Abstract

Newly emerged molecular markers in gliomas provide prognostic values beyond the capabilities of histologic classification. BRAF mutation, especially BRAF V600E, is common in a subset of gliomas and may represent a potential prognostic marker. The aim of our study is to investigate the potential use of BRAF mutations on prognosis of glioma patients. Four electronic databases were searched for potential articles, including PubMed, Scopus, ISI Web of Science, and Virtual Health Library (VHL). Data of hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were directly obtained from original papers or indirectly estimated from Kaplan Meier curve (KMC). A random effect model weighted by inverse variance method was used to calculate the pooled HR. From 705 articles, we finally included 11 articles with 1308 glioma patients for the final analysis. The overall estimates showed that BRAF V600E was associated with an improved overall survival (OS) in glioma patients (HR = 0.60; 95% CI = 0.44-0.80). Results for progression-free survival (PFS), however, were not statistically significant (HR = 1.39; 95% CI = 0.82-2.34). In subgroup analyses, BRAF V600E showed its effect in improving survival in pediatric and young adult gliomas (under 35 years) but did not have prognostic value in old adult. Additionally, BRAF V600E was only associated with a favorable prognosis in lower grade glioma. Our meta-analysis provides evidence that BRAF mutation has a favorable prognostic impact in gliomas and its prognostic value might be dependent on patient age and tumor grade. This mutation can be used as a prognostic factor in glioma but additional studies are required to clarify its prognostic value taking into account other confounding factors.

Citing Articles

Exploring glioma heterogeneity through omics networks: from gene network discovery to causal insights and patient stratification.

Kastendiek N, Coletti R, Gross T, Lopes M BioData Min. 2024; 17(1):56.

PMID: 39696678 PMC: 11657291. DOI: 10.1186/s13040-024-00411-y.

A Synopsis of Biomarkers in Glioblastoma: Past and Present.

Tataranu L, Turliuc S, Rizea R, Dricu A, Alexandru O, Staicu G Curr Issues Mol Biol. 2024; 46(7):6903-6939.

PMID: 39057054 PMC: 11275428. DOI: 10.3390/cimb46070412.

Potential Diagnostic and Clinical Significance of Selected Genetic Alterations in Glioblastoma.

Tomoszkova S, Skarda J, Lipina R Int J Mol Sci. 2024; 25(8).

PMID: 38674026 PMC: 11050250. DOI: 10.3390/ijms25084438.

Personalized Medicine in Brain Gliomas: Targeted Therapy, Patient-Derived Tumor Models (Review).

Yashin K, Yuzhakova D, Sachkova D, Kukhnina L, Kharitonova T, Zolotova A Sovrem Tekhnologii Med. 2024; 15(3):61-71.

PMID: 38435477 PMC: 10904359. DOI: 10.17691/stm2023.15.3.07.

Benign Glioma.

Wu P, Filley A, Miller M, Bruce J Adv Exp Med Biol. 2023; 1405:31-71.

PMID: 37452934 DOI: 10.1007/978-3-031-23705-8_2.

References

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

Park C, Lee S, Kim J, Kim J, Kim T, Lee S . Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget. 2014; 5(10):3399-407. PMC: 4102818. DOI: 10.18632/oncotarget.1975. View

Bannykh S, Mirocha J, Nuno M, Lopategui J, Kandala G . V600E BRAF mutation in pilocytic astrocytoma is associated with a more diffuse growth pattern but does not confer a more aggressive clinical behavior. Clin Neuropathol. 2014; 33(6):388-98. DOI: 10.5414/NP300753. View

Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H . A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun. 2016; 4(1):79. PMC: 4977715. DOI: 10.1186/s40478-016-0351-2. View

Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C . Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011; 121(3):397-405. DOI: 10.1007/s00401-011-0802-6. View

Safaee Ardekani G, Jafarnejad S, Tan L, Saeedi A, Li G . The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One. 2012; 7(10):e47054. PMC: 3467229. DOI: 10.1371/journal.pone.0047054. View

Killela P, Pirozzi C, Healy P, Reitman Z, Lipp E, Rasheed B . Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 2014; 5(6):1515-25. PMC: 4039228. DOI: 10.18632/oncotarget.1765. View

Li C, Lee K, Schneider E, Zeiger M . BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012; 97(12):4559-70. PMC: 3513529. DOI: 10.1210/jc.2012-2104. View

10.

Cruz G, Oliveira I, Moraes L, Paniago M, Alves M, Capellano A . Analysis of KIAA1549-BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas. J Neurooncol. 2014; 117(2):235-42. DOI: 10.1007/s11060-014-1398-1. View

11.

Phillips H, Kharbanda S, Chen R, Forrest W, Soriano R, Wu T . Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9(3):157-73. DOI: 10.1016/j.ccr.2006.02.019. View

12.

Holderfield M, Deuker M, McCormick F, McMahon M . Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014; 14(7):455-67. PMC: 4250230. DOI: 10.1038/nrc3760. View

13.

Chan A, Yao Y, Zhang Z, Shi Z, Chen L, Chung N . Combination genetic signature stratifies lower-grade gliomas better than histological grade. Oncotarget. 2015; 6(25):20885-901. PMC: 4673237. DOI: 10.18632/oncotarget.4928. View

14.

Tabouret E, Bequet C, Denicolai E, Barrie M, Nanni I, Metellus P . BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma. Eur J Surg Oncol. 2015; 41(12):1685-90. DOI: 10.1016/j.ejso.2015.09.012. View

15.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

16.

Ho C, Mobley B, Gordish-Dressman H, VandenBussche C, Mason G, Bornhorst M . A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. Acta Neuropathol. 2015; 130(4):575-85. DOI: 10.1007/s00401-015-1467-3. View

17.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

18.

Horbinski C, Nikiforova M, Hagenkord J, Hamilton R, Pollack I . Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol. 2012; 14(6):777-89. PMC: 3367847. DOI: 10.1093/neuonc/nos077. View

19.

Mistry M, Zhukova N, Merico D, Rakopoulos P, Krishnatry R, Shago M . BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015; 33(9):1015-22. PMC: 4356711. DOI: 10.1200/JCO.2014.58.3922. View

20.

Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D . Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol. 2015; 129(5):669-78. DOI: 10.1007/s00401-015-1405-4. View